Samsung Bioepis Obtains First Drug Approval in the United States as the U.S....
Monday April 24th 2017 at 506am UTC INCHEON Korea&8211;BUSINESS WIRE&8211; Samsung Bioepis Co. Ltd. today announced that the U.S. Food and Drug Administration FDA has approved RENFLEXIS...
View ArticleRedHill Biopharma Announces Enrollment of Last Patient in the BEKINDAĆ Phase...
Topline results are expected in the third quarter of 2017 The randomized doubleblind placebocontrolled Phase II study is evaluating the safety and efficacy of BEKINDAĆ RHB102 12 mg in 127 U.S. patients...
View ArticleInterleukin23 Inhibitor Passes Phase II in Crohn Disease
Risankizumab should proceed to phase III trials for moderatetosevere Crohn disease.
View ArticleInnovent Biologics Inc Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryInnovent Biologics Inc Innovent Biologics is a biopharmaceutical company that discovers develops and manufactures monoclonal antibodies. The company's product portfolio comprise monoclonal...
View ArticleTiGenix NV TIG Pharmaceuticals Healthcare Deals and Alliances Profile Updated...
SummaryTiGenix NV TiGenix is a biopharmaceutical company that develops and commercializes novel therapeutics. Its product portfolio includes AlloCSC01 AlloCSC02 Cx611 and Cx601. The company develops...
View ArticleImmune Pharmaceuticals Inc IMNP Pharmaceuticals Healthcare Deals and...
SummaryImmune Pharmaceuticals Inc Immune Pharma formerly EpiCept Corporation is a pharmaceutical company that develops antibody therapeutics for the treatment of patients with inflammatory diseases and...
View ArticleCrohn's & Colitis Foundation launches 2017 indoor cycling event lineup with...
NEW YORK April 26 2017 PRNewswire Today the Crohn's & Colitis Foundation launched its spin4 crohn's & colitis cures indoor cycling event lineup for 2017 with a new program video....
View ArticleSamsung Bioepis Biosimilar Version of Remicade Receives FDA Approval
INCHEON Korea April 24 2017 Samsung Bioepis Co. Ltd. today announced that the U.S. Food and Drug Administration FDA has approved RENFLEXIS infliximababda a biosimilar referencing RemicadeĆi infliximab...
View ArticleAmgen Reports First Quarter 2017 Financial Results
THOUSAND OAKS Calif. April 26 2017 PRNewswire Amgen NASDAQAMGN today announced financial results for the first quarter of 2017. Key results include Total revenues decreased 1 percent versus the first...
View ArticleGlobal Ileostomy Market to Reach US$1.65 Billion by 2024 Government...
ALBANY New York April 27 2017 PRNewswire The most prominent companies in the global ileostomy market are Coloplast Convatec and Hollister. Among these Coloplast held the dominant share of 36 in the...
View ArticleCelgene Reports First Quarter 2017 Operating and Financial Results
Net Product Sales of $2.95B in Q117; Increased 18 YY REVLIMIDĆ Net Product Sales of $1.9B in Q117; Increased 20 YY Raising 2017 EPS Guidance Positive phase II STEPSTONE data with ozanimod in Crohns dis...
View ArticleTxCell SA TXCL Pharmaceuticals Healthcare Deals and Alliances Profile Updated...
SummaryTxcell SA Txcell is a biotechnology company that develops and innovates cellbased immunotherapy utilizing antigen specific regulatory Tcells with focus on chronic inflammatory and autoimmune...
View ArticleNICE backs new option for Crohns disease
The National Institute for Health and Care Excellence is backing the use of Janssen’s biologic Stelara to treat adult patients with moderately to severely active Crohn’s disease.
View ArticleMedical News Today Soy protein may improve symptoms of inflammatory bowel...
Consumption of soy protein may alleviate some of the symptoms associated with inflammatory bowel diseases such as Crohns disease and ulcerative colitis.
View ArticleOncogenic Bcl3 Protein Linked to Chronic Intestinal Inflammation
A scientific team&160;reports that high levels of the oncogenic Bcl3 protein lead to chronic intestinal diseases. Their study "Elevated&160; levels of Bcl3 inhibits Treg development...
View ArticleWidespread Vitamin D Deficiency Likely Due to Sunscreen Use Increase of...
CHICAGO May 1 2017 PRNewswireUSNewswire Results from a clinical review published in The Journal of the American Osteopathic Association find nearly 1 billion people worldwide may have deficient or...
View ArticleHospitalizations for Crohn's Disease U.S. 20032013
Have hospitalizations for Crohn's disease changed significantly over time This study examined trends in colorectal resection and fistula repair rates over a 10 year period. Morbidity & Mortality...
View ArticleTop Low Dose Naltrexone Practitioners to Speak at LDN Research Trusts 4th...
Portland OR May 01 2017 PR.com The LDN Research Trust the nonprofit organization and charity dedicated to raising awareness of Low Dose Naltrexone LDN as well as funding research and clinical trials of...
View ArticleArena Pharmaceuticals to Release First Quarter 2017 Financial Results and...
SAN DIEGO May 2 2017 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA a biopharmaceutical company focused on developing novel small molecule drugs across multiple therapeutic areas today announced...
View Article